RS51973B - Stabilni farmaceutski preparati koji sadrže fezoterodin - Google Patents

Stabilni farmaceutski preparati koji sadrže fezoterodin

Info

Publication number
RS51973B
RS51973B RS20110469A RSP20110469A RS51973B RS 51973 B RS51973 B RS 51973B RS 20110469 A RS20110469 A RS 20110469A RS P20110469 A RSP20110469 A RS P20110469A RS 51973 B RS51973 B RS 51973B
Authority
RS
Serbia
Prior art keywords
fesoterodine
pharmaceutical preparation
preparation according
xylitol
stabilizer
Prior art date
Application number
RS20110469A
Other languages
English (en)
Serbian (sr)
Inventor
Christoph Dr. Arth
Hans-Jürgen dr. MIKA
Michael Dr. Komenda
Hans Dr. Lindner
Fatima Dr. Bicane
Kerstin Dr. Paulus
Meike Dr. Irngartigner
Original Assignee
Ucb Pharma Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51973(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Gmbh. filed Critical Ucb Pharma Gmbh.
Publication of RS51973B publication Critical patent/RS51973B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20110469A 2006-06-09 2007-06-06 Stabilni farmaceutski preparati koji sadrže fezoterodin RS51973B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011942 2006-06-09
EP06011941 2006-06-09
EP06011943 2006-06-09

Publications (1)

Publication Number Publication Date
RS51973B true RS51973B (sr) 2012-02-29

Family

ID=38521333

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20110469A RS51973B (sr) 2006-06-09 2007-06-06 Stabilni farmaceutski preparati koji sadrže fezoterodin

Country Status (37)

Country Link
EP (1) EP2029134B1 (cg-RX-API-DMAC7.html)
JP (2) JP4743321B2 (cg-RX-API-DMAC7.html)
KR (1) KR101316773B1 (cg-RX-API-DMAC7.html)
CN (1) CN101466371B (cg-RX-API-DMAC7.html)
AP (1) AP2416A (cg-RX-API-DMAC7.html)
AR (1) AR061289A1 (cg-RX-API-DMAC7.html)
AT (1) ATE517619T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007255408B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0712865B1 (cg-RX-API-DMAC7.html)
CA (1) CA2652712C (cg-RX-API-DMAC7.html)
CR (1) CR10494A (cg-RX-API-DMAC7.html)
CU (1) CU23850B1 (cg-RX-API-DMAC7.html)
CY (1) CY1111934T1 (cg-RX-API-DMAC7.html)
DK (1) DK2029134T3 (cg-RX-API-DMAC7.html)
EA (1) EA015909B9 (cg-RX-API-DMAC7.html)
EC (1) ECSP089010A (cg-RX-API-DMAC7.html)
ES (1) ES2370943T3 (cg-RX-API-DMAC7.html)
GT (1) GT200800276A (cg-RX-API-DMAC7.html)
HR (1) HRP20110776T1 (cg-RX-API-DMAC7.html)
IL (2) IL195732A (cg-RX-API-DMAC7.html)
MA (1) MA30504B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008015736A (cg-RX-API-DMAC7.html)
MY (1) MY146574A (cg-RX-API-DMAC7.html)
NI (1) NI200800318A (cg-RX-API-DMAC7.html)
NL (1) NL2000690C2 (cg-RX-API-DMAC7.html)
NO (1) NO341980B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ572616A (cg-RX-API-DMAC7.html)
PE (2) PE20080331A1 (cg-RX-API-DMAC7.html)
PL (1) PL2029134T3 (cg-RX-API-DMAC7.html)
PT (1) PT2029134E (cg-RX-API-DMAC7.html)
RS (1) RS51973B (cg-RX-API-DMAC7.html)
SI (1) SI2029134T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN08505A1 (cg-RX-API-DMAC7.html)
TW (2) TWI520735B (cg-RX-API-DMAC7.html)
UY (1) UY30394A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007141298A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200806411B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294047A2 (en) * 2008-04-04 2011-03-16 Actavis Group PTC EHF Novel mandelate salt of fesoterodine
IT1392082B1 (it) 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
KR20120014583A (ko) 2009-05-11 2012-02-17 라티오팜 게엠베하 타르타르산 염 형태의 데스페소테로딘
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
EP2549985A1 (en) * 2010-03-22 2013-01-30 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
US20140199401A1 (en) * 2011-07-04 2014-07-17 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
WO2013046194A2 (en) * 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
US20150182629A1 (en) * 2012-07-02 2015-07-02 Hetero Research Foundation Stable compositions of fesoterodine
KR20250154562A (ko) 2012-11-02 2025-10-28 머레이 앤 풀 엔터프라이지즈, 리미티드 콜히친 유도체의 투여를 통한 심혈관성 병태의 치료 또는 예방
EA037375B1 (ru) 2013-04-16 2021-03-22 Марри Энд Пул Энтерпрайзес Лимитед Составы с замедленным высвобождением, содержащие колхицин, и способы их применения
DK2986280T3 (da) * 2013-04-16 2021-06-14 Murray & Poole Entpr Ltd Formuleringer med langvarig frigivelse af colchicin og fremgangsmåder til brug af samme
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (en) 2017-07-12 2019-01-17 Rontis Hellas S.A. EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
WO2019132832A1 (en) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet compositions of fesoterodine fumarate
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
WO2019206391A1 (en) 2018-04-26 2019-10-31 Rontis Hellas S.A. Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
CA3187827A1 (en) * 2020-06-30 2022-01-06 Imbria Pharmaceuticals, Inc. Modified release formulations of modified forms of trimetazidine
JPWO2023145486A1 (cg-RX-API-DMAC7.html) * 2022-01-28 2023-08-03

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253877T3 (es) * 1998-03-03 2006-06-01 SHIONOGI & CO., LTD. Composiciones farmaceuticas que contienen el inhibidor de fosfolipasa((3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1h-indol-4-il)oxi)acetato de sodio.
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Schwarz Pharma Ag, 40789 Monheim Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
DE10224107A1 (de) 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Also Published As

Publication number Publication date
IL220800A (en) 2015-03-31
EP2029134B1 (en) 2011-07-27
ATE517619T1 (de) 2011-08-15
KR101316773B1 (ko) 2013-10-15
CA2652712C (en) 2014-04-01
CN101466371A (zh) 2009-06-24
MY146574A (en) 2012-08-30
NO341980B1 (no) 2018-03-05
AP2008004673A0 (en) 2008-12-31
SI2029134T1 (sl) 2012-01-31
PT2029134E (pt) 2011-11-02
CA2652712A1 (en) 2007-12-13
GT200800276A (es) 2009-06-18
CU23850B1 (es) 2012-10-15
AU2007255408A1 (en) 2007-12-13
AU2007255408B2 (en) 2013-03-14
TNSN08505A1 (fr) 2010-04-14
CU20080235A7 (es) 2011-04-26
CR10494A (es) 2009-01-19
DK2029134T3 (da) 2011-10-17
NI200800318A (es) 2011-01-12
IL195732A0 (en) 2009-09-01
UY30394A1 (es) 2007-11-30
TWI520735B (zh) 2016-02-11
KR20090026135A (ko) 2009-03-11
NZ572616A (en) 2010-11-26
PE20080331A1 (es) 2008-06-19
CY1111934T1 (el) 2015-11-04
MX2008015736A (es) 2009-01-09
HK1128626A1 (en) 2009-11-06
HRP20110776T1 (hr) 2011-11-30
JP2011140498A (ja) 2011-07-21
NO20090141L (no) 2009-01-09
EA015909B9 (ru) 2012-03-30
JP4743321B2 (ja) 2011-08-10
EP2029134A1 (en) 2009-03-04
ZA200806411B (en) 2009-05-27
WO2007141298A1 (en) 2007-12-13
ECSP089010A (es) 2009-01-30
CN101466371B (zh) 2011-10-05
AP2416A (en) 2012-06-01
EA200802444A1 (ru) 2009-06-30
TW201336491A (zh) 2013-09-16
NL2000690C2 (nl) 2008-04-01
BRPI0712865B1 (pt) 2021-08-17
JP2009539802A (ja) 2009-11-19
MA30504B1 (fr) 2009-06-01
PL2029134T3 (pl) 2011-12-30
BRPI0712865A2 (pt) 2012-12-18
TWI397409B (zh) 2013-06-01
TW200814992A (en) 2008-04-01
PE20120476A1 (es) 2012-04-20
EA015909B1 (ru) 2011-12-30
AR061289A1 (es) 2008-08-20
IL195732A (en) 2013-09-30
ES2370943T3 (es) 2011-12-23
JP4781489B2 (ja) 2011-09-28
NL2000690A1 (nl) 2007-12-11

Similar Documents

Publication Publication Date Title
RS51973B (sr) Stabilni farmaceutski preparati koji sadrže fezoterodin
AU2019268052B2 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
US9364541B2 (en) Pharmaceutical compositions comprising Fesoterodine
KR20110116027A (ko) 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 의약 포뮬레이션
RS51527B (sr) Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so, postupak za proizvodnju iste i njena primena
US20130236544A1 (en) Stable pharmaceutical compositions of fesoterodine
WO2000037054A1 (en) A pharmaceutical mixture comprising a profen
JP7195354B2 (ja) 浸食マトリックス中に1またはそれ以上のフマル酸エステルを含む医薬製剤
HK1128626B (en) Stabilized pharmaceutical compositions comprising fesoterodine
HK40009517A (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose